US6489346B1
(en)
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US8231899B2
(en)
*
|
1998-09-10 |
2012-07-31 |
Nycomed Danmark Aps |
Quick release pharmaceutical compositions of drug substances
|
SA99191255B1
(ar)
*
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US20020035107A1
(en)
|
2000-06-20 |
2002-03-21 |
Stefan Henke |
Highly concentrated stable meloxicam solutions
|
EP1250921A1
(en)
*
|
2001-04-21 |
2002-10-23 |
BOEHRINGER INGELHEIM INTERNATIONAL GmbH |
Fast disintegrating meloxicam tablet
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
DE10161077A1
(de)
|
2001-12-12 |
2003-06-18 |
Boehringer Ingelheim Vetmed |
Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
|
US20030161875A1
(en)
*
|
2002-02-27 |
2003-08-28 |
Deepak Murpani |
Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
|
US8992980B2
(en)
|
2002-10-25 |
2015-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Water-soluble meloxicam granules
|
US20040109889A1
(en)
*
|
2002-12-04 |
2004-06-10 |
Bunick Frank J. |
Surface treatment composition for soft substrates
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
JP2009513512A
(ja)
*
|
2003-07-09 |
2009-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
メロキシカムを含む組成物
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
EP1568369A1
(en)
|
2004-02-23 |
2005-08-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of meloxicam for the treatment of respiratory diseases in pigs
|
US20050220877A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Patel Ashish A |
Bilayer tablet comprising an antihistamine and a decongestant
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
CA2572359C
(en)
*
|
2004-06-29 |
2010-08-03 |
Nycomed Danmark Aps |
Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
|
JP5490347B2
(ja)
*
|
2005-05-27 |
2014-05-14 |
エスエス製薬株式会社 |
経口投与用製剤
|
JO3352B1
(ar)
|
2005-06-17 |
2019-03-13 |
Apr Applied Pharma Res Sa |
صيغ دايكلوفيناك وطرق استخدامه
|
US20100204333A1
(en)
|
2005-07-20 |
2010-08-12 |
Panacea Biotec Ltd. |
Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
|
BRPI0613611A2
(pt)
*
|
2005-07-22 |
2011-01-18 |
Myriad Genetics Inc |
formulações de alta concentração de fármaco e formas de dosagens
|
CN103214483B
(zh)
|
2005-12-13 |
2014-12-17 |
因塞特公司 |
作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
|
US20070154542A1
(en)
*
|
2005-12-30 |
2007-07-05 |
Cogentus Pharmaceuticals, Inc. |
Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
|
WO2007130507A2
(en)
*
|
2006-05-03 |
2007-11-15 |
Proethic Pharmaceuticals, Inc. |
Acute pain medications based on fast acting diclofenac-opioid combinations
|
WO2008008120A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Fmc Corporation |
Solid form
|
WO2008062449A2
(en)
*
|
2006-09-18 |
2008-05-29 |
Glenmark Pharmaceuticals Limited |
A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20080311162A1
(en)
*
|
2007-05-16 |
2008-12-18 |
Olivia Darmuzey |
Solid form
|
EP2740731B1
(en)
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
WO2009034558A2
(en)
|
2007-09-14 |
2009-03-19 |
Wockhardt Research Centre |
Rhein or diacerein compositions
|
WO2009089134A1
(en)
|
2008-01-04 |
2009-07-16 |
Src, Inc. |
Methods for measuring a patint response upon administration of a drug and compositions thereof
|
AU2009249069A1
(en)
|
2008-05-20 |
2009-11-26 |
Neurogesx, Inc. |
Carbonate prodrugs and methods of using the same
|
AU2009249067A1
(en)
|
2008-05-20 |
2009-11-26 |
Neurogesx, Inc. |
Water-soluble acetaminophen analogs
|
AU2009290712A1
(en)
|
2008-09-09 |
2010-03-18 |
Astrazeneca Ab |
Method for delivering a pharmaceutical composition to patient in need thereof
|
DK2432472T3
(da)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
|
JP2012531430A
(ja)
*
|
2009-06-25 |
2012-12-10 |
ポーゼン インコーポレイテッド |
アスピリン療法を必要とする患者を治療するための方法
|
AU2010263304A1
(en)
|
2009-06-25 |
2012-02-02 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an NSAID-associated ulcer
|
TW201113285A
(en)
*
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US9101529B2
(en)
|
2009-10-12 |
2015-08-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Containers for compositions comprising meloxicam
|
WO2011107150A1
(en)
|
2010-03-03 |
2011-09-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
|
KR102283091B1
(ko)
|
2010-03-10 |
2021-07-30 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
US9795568B2
(en)
|
2010-05-05 |
2017-10-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Low concentration meloxicam tablets
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
EP2394641A1
(en)
|
2010-05-30 |
2011-12-14 |
Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi |
Pharmaceutical formulations of lornoxicam
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
WO2012146314A1
(en)
|
2011-04-29 |
2012-11-01 |
Refarmed Chemicals Sa |
Thin gelatin capsules for rapid drug release in the mouth
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
JP2012012411A
(ja)
*
|
2011-10-03 |
2012-01-19 |
Ssp Co Ltd |
経口投与用製剤
|
CA2860231A1
(en)
|
2011-12-28 |
2013-07-04 |
Pozen Inc. |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
BR112014024382B1
(pt)
|
2012-04-18 |
2022-08-09 |
SpecGx LLC |
Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação
|
US9308196B2
(en)
*
|
2012-05-18 |
2016-04-12 |
Gruenenthal Gmbh |
Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
|
US20130310385A1
(en)
|
2012-05-18 |
2013-11-21 |
Gruenenthal Gmbh |
Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
|
US9320729B2
(en)
|
2012-05-18 |
2016-04-26 |
Gruenenthal Gmbh |
Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
|
US9855286B2
(en)
|
2012-05-18 |
2018-01-02 |
Gruenenthal Gmbh |
Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
|
US20130310435A1
(en)
|
2012-05-18 |
2013-11-21 |
Gruenenthal Gmbh |
Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CR20190073A
(es)
|
2012-11-15 |
2019-04-25 |
Incyte Holdings Corp |
FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
WO2014152296A1
(en)
|
2013-03-15 |
2014-09-25 |
Mallinckrodt Llc |
Abuse deterrent solid dosage form for immediate release with functional score
|
JP2013216701A
(ja)
*
|
2013-07-29 |
2013-10-24 |
Ssp Co Ltd |
経口投与用製剤
|
KR101890649B1
(ko)
*
|
2013-07-30 |
2018-09-28 |
라이온 가부시키가이샤 |
정제
|
EP3030227B1
(en)
|
2013-08-07 |
2020-04-08 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
JP6850131B2
(ja)
|
2014-07-03 |
2021-03-31 |
スペックジーエックス エルエルシー |
非セルロース多糖を含む、乱用抑止性即時放出製剤
|
WO2017048720A1
(en)
|
2015-09-15 |
2017-03-23 |
Praxis Biosciences, Llc |
Prodrugs of fencamfamine
|
UA126916C2
(uk)
|
2017-04-27 |
2023-02-22 |
Др. Редді'З Лабораторіз Лімітед |
Фармацевтична композиція кеторолаку
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
PE20211310A1
(es)
|
2018-01-30 |
2021-07-22 |
Incyte Corp |
Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento
|
JP2021519775A
(ja)
|
2018-03-30 |
2021-08-12 |
インサイト・コーポレイションIncyte Corporation |
Jak阻害剤を用いる化膿性汗腺炎の治療
|
JP7170437B2
(ja)
*
|
2018-06-29 |
2022-11-14 |
小林製薬株式会社 |
内服用医薬組成物
|
MX2021002459A
(es)
|
2018-09-25 |
2021-04-29 |
SpecGx LLC |
Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
|
US11779541B2
(en)
*
|
2019-03-26 |
2023-10-10 |
Johnson & Johnson Consumer Inc. |
Immediate release dosage form
|
CN115038443A
(zh)
|
2019-11-22 |
2022-09-09 |
因西特公司 |
包含alk2抑制剂和jak2抑制剂的组合疗法
|
JP7499025B2
(ja)
|
2019-12-27 |
2024-06-13 |
小林製薬株式会社 |
内服用医薬組成物
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11324727B2
(en)
|
2020-07-15 |
2022-05-10 |
Schabar Research Associates, Llc |
Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
|
JP2023534810A
(ja)
|
2020-07-15 |
2023-08-14 |
シャバー リサーチ アソシエイツ エルエルシー |
急性痛の処置並びに胸やけの重症度及び/又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
|